{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:37:29Z","timestamp":1790300249299,"version":"4.1.0"},"reference-count":48,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Stroke-induced spasticity is a prevalent condition affecting stroke survivors, significantly impacting their quality of life. Botulinum Toxin A injections are widely used for its management, yet the long-term effects and optimal management strategies remain uncertain. This retrospective study analyzed medical records of 95 chronic stroke patients undergoing long-term BoNT-A treatment for spasticity. Demographic data, treatment duration, dosage variability, and dropout rates were assessed over a period ranging from 2 to 14 years. The study revealed a notable extension of the interval between BoNT-A injections throughout the treatment duration. Dropout rates peaked during the initial 5 years of treatment, perhaps due to perceived treatment ineffectiveness. Additionally, a trend of escalating dosage was observed across all groups, indicating a potential rise in the severity of spasticity or changes in treatment response over time. BoNT-A injections emerged as the predominant treatment choice for managing post-stroke spasticity. The delayed initiation of BoNT-A treatment underscores the need for heightened awareness among healthcare providers to recognize and manage spasticity promptly post-stroke. Patients\u2019 expectations and treatment goals should be clearly defined to optimize treatment adherence, while the observed escalation in dosage and treatment intervals emphasizes the dynamic nature of spasticity and underscores the importance of monitoring long-term treatment outcomes.<\/jats:p>","DOI":"10.3390\/toxins16090383","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T08:38:47Z","timestamp":1725352727000},"page":"383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-Term Management of Post-Stroke Spasticity with Botulinum Toxin: A Retrospective Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2284-2950","authenticated-orcid":false,"given":"Nicoletta","family":"Falcone","sequence":"first","affiliation":[{"name":"Department of Traslational Research and New Technologies in Medicine and Surgery, Unit of Neurorehabilitation, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4095-7785","authenticated-orcid":false,"given":"Fabrizio","family":"Leo","sequence":"additional","affiliation":[{"name":"Neurorehabilitation Unit, Department of Neuroscience, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1043-7738","authenticated-orcid":false,"given":"Carmelo","family":"Chisari","sequence":"additional","affiliation":[{"name":"Department of Traslational Research and New Technologies in Medicine and Surgery, Unit of Neurorehabilitation, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1422-1539","authenticated-orcid":false,"given":"Stefania","family":"Dalise","sequence":"additional","affiliation":[{"name":"Neurorehabilitation Unit, Department of Neuroscience, University Hospital of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1212\/WNL.0000000000012781","article-title":"Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions","volume":"97","author":"Saini","year":"2021","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Platz, T. (2021). Post-Stroke Spasticity\u2014Clinical Pathways in Stroke Rehabilitation: Evidence-Based Clinical Practice Recommendations, Springer International Publishing.","DOI":"10.1007\/978-3-030-58505-1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.0b013e3182762448","article-title":"Toward an Epidemiology of Poststroke Spasticity","volume":"80","author":"Wissel","year":"2013","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sakas, D.E., Simpson, B.A., and Krames, E.S. (2007). The Phenomenon of Spasticity: A Pathophysiological and Clinical Introduction to Neuromodulation Therapies BT\u2014Operative Neuromodulation: Volume 1: Functional Neuroprosthetic Surgery. An Introduction, Springer.","DOI":"10.1007\/978-3-211-33079-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00415-018-8759-1","article-title":"Defining Spasticity: A New Approach Considering Current Movement Disorders Terminology and Botulinum Toxin Therapy","volume":"265","author":"Dressler","year":"2018","journal-title":"J. Neurol."},{"key":"ref_6","first-page":"453","article-title":"Spasticity in neurological pathologies. An update on the pathophysiological mechanisms, advances in diagnosis and treatment","volume":"70","author":"Albu","year":"2020","journal-title":"Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1161\/01.STR.0000180861.54180.FF","article-title":"Management of Adult Stroke Rehabilitation Care","volume":"36","author":"Duncan","year":"2005","journal-title":"Stroke"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jacinto, J., Balbert, A., Bensmail, D., Carda, S., Draulans, N., Deltombe, T., Ketchum, N., Molteni, F., and Reebye, R. (2023). Selecting Goals and Target Muscles for Botulinum Toxin A Injection Using the Goal Oriented Facilitated Approach to Spasticity Treatment (GO-FAST) Tool. Toxins, 15.","DOI":"10.3390\/toxins15120676"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Suputtitada, A., Chatromyen, S., Chen, C.P.C., and Simpson, D.M. (2024). Best Practice Guidelines for the Management of Patients with Post-Stroke Spasticity: A Modified Scoping Review. Toxins, 16.","DOI":"10.3390\/toxins16020098"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lee, J.-H., and Kim, E.-J. (2023). The Effects of Shock Wave Therapy on Spasticity and Walking Ability in People with Stroke: A Comparative Study of Different Application Sites. Brain Sci., 13.","DOI":"10.3390\/brainsci13040687"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.23736\/S1973-9087.22.07136-2","article-title":"A Systematic Review on Extracorporeal Shock Wave Therapy and Botulinum Toxin for Spasticity Treatment: A Comparison on Efficacy","volume":"58","author":"Mihai","year":"2022","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00002018-200629010-00003","article-title":"Botulinum Toxin Treatment of Adult Spasticity: A Benefit-Risk Assessment","volume":"29","author":"Sheean","year":"2006","journal-title":"Drug Saf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/toxins4111196","article-title":"Emerging Opportunities for Serotypes of Botulinum Neurotoxins","volume":"4","author":"Morris","year":"2012","journal-title":"Toxins"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Scaglione, F. (2016). Conversion Ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in Clinical Practice. Toxins, 8.","DOI":"10.3390\/toxins8030065"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Field, M., Splevins, A., Picaut, P., Van der Schans, M., Langenberg, J., Noort, D., and Foster, K. (2018). AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins, 10.","DOI":"10.3390\/toxins10120535"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2015.01.033","article-title":"Employment of Higher Doses of Botulinum Toxin Type A to Reduce Spasticity after Stroke","volume":"350","author":"Santamato","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.toxicon.2021.09.020","article-title":"The Effectiveness of Botulinum Toxin on Spasticity and Gait of Hemiplegic Patients after Stroke: A Systematic Review and Meta-Analysis","volume":"203","author":"Varvarousis","year":"2021","journal-title":"Toxicon"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Masakado, Y., Kagaya, H., Kondo, K., Otaka, Y., Dekundy, A., Hanschmann, A., Geister, T.L., and Kaji, R. (2022). Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.832937"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PHM.0000000000000208","article-title":"Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Adult Upper Limb Spasticity","volume":"94","author":"Dashtipour","year":"2015","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chiu, S.Y., Patel, B., Burns, M.R., Legacy, J., Shukla, A.W., Ramirez-Zamora, A., Deeb, W., and Malaty, I.A. (2020). High-Dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy. Tremor Other Hyperkinet. Mov., 10.","DOI":"10.5334\/tohm.527"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00702-012-0892-x","article-title":"Efficacy and Safety of Higher Doses of Botulinum Toxin Type A NT 201 Free from Complexing Proteins in the Upper and Lower Limb Spasticity after Stroke","volume":"120","author":"Santamato","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1590\/S0004-282X2007000400008","article-title":"Does Botulinum Toxin Improve the Function of the Patient with Spasticity after Stroke?","volume":"65","author":"Cardoso","year":"2007","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1589\/jpts.27.759","article-title":"Gait Improvement by Low-Dose Botulinum Toxin A Injection Treatment of the Lower Limbs in Subacute Stroke Patients","volume":"27","author":"Tao","year":"2015","journal-title":"J. Phys. Ther. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/STROKEAHA.110.582197","article-title":"Botulinum Toxin for the Upper Limb After Stroke (BoTULS) Trial","volume":"42","author":"Shaw","year":"2011","journal-title":"Stroke"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.rehab.2018.05.1320","article-title":"Does Botulinum Toxin Treatment Improve Upper Limb Active Function?","volume":"62","author":"Levy","year":"2019","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jns.2017.04.052","article-title":"Long-Term Safety of Repeated High Doses of IncobotulinumtoxinA Injections for the Treatment of Upper and Lower Limb Spasticity after Stroke","volume":"378","author":"Santamato","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00002060-200007000-00010","article-title":"Post-Stroke Spasticity Management with Repeated Botulinum Toxin Injections in the Upper Limb","volume":"79","author":"Lagalla","year":"2000","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hamaguchi, T., Abo, M., Murata, K., Kenmoku, M., Yoshizawa, I., Ishikawa, A., Suzuki, M., Nakaya, N., and Taguchi, K. (2019). Association of Long-Term Treatment by Botulinum Neurotoxins and Occupational Therapy with Subjective Physical Status in Patients with Post-Stroke Hemiplegia. Toxins, 11.","DOI":"10.3390\/toxins11080453"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1179\/016164109X12478302362734","article-title":"Long-Term Treatment of Spasticity with Botulinum Toxin Type A: An Analysis of 1221 Treatments in 137 Patients","volume":"32","author":"Mohammadi","year":"2010","journal-title":"Neurol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/ene.13902","article-title":"Prevalence and Evolution of Spasticity in Patients Suffering from First-Ever Stroke with Carotid Origin: A Prospective, Longitudinal Study","volume":"26","author":"Srp","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.apmr.2011.06.027","article-title":"Occurrence and Temporal Evolution of Upper Limb Spasticity in Stroke Patients Admitted to a Rehabilitation Unit","volume":"93","author":"Kong","year":"2012","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Li, S. (2017). Spasticity, Motor Recovery, and Neural Plasticity after Stroke. Front. Neurol., 8.","DOI":"10.3389\/fneur.2017.00120"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Azzollini, V., Dalise, S., and Chisari, C. (2021). How Does Stroke Affect Skeletal Muscle? State of the Art and Rehabilitation Perspective. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.797559"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kaya, C.S., Y\u0131lmaz, E.O., Akdeniz-Do\u011fan, Z.D., and Yucesoy, C.A. (2020). Long-Term Effects With Potential Clinical Importance of Botulinum Toxin Type-A on Mechanics of Muscles Exposed. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.00738"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Battaglia, M., Cosenza, L., Scotti, L., Bertoni, M., Polverelli, M., Loro, A., Santamato, A., and Baricich, A. (2021). Triceps Surae Muscle Characteristics in Spastic Hemiparetic Stroke Survivors Treated with Botulinum Toxin Type A: Clinical Implications from Ultrasonographic Evaluation. Toxins, 13.","DOI":"10.3390\/toxins13120889"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mus.24763","article-title":"Muscle Histopathology in Children with Spastic Cerebral Palsy Receiving Botulinum Toxin Type A","volume":"53","author":"Valentine","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ultrasmedbio.2008.09.016","article-title":"Skeletal Muscle Ultrasound: Correlation Between Fibrous Tissue and Echo Intensity","volume":"35","author":"Pillen","year":"2009","journal-title":"Ultrasound Med. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.apmr.2012.02.005","article-title":"Is Spastic Muscle Echo Intensity Related to the Response to Botulinum Toxin Type A in Patients With Stroke? A Cohort Study","volume":"93","author":"Picelli","year":"2012","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00415-010-5463-1","article-title":"Early Development of Spasticity Following Stroke: A Prospective, Observational Trial","volume":"257","author":"Wissel","year":"2010","journal-title":"J. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11795735211036576","DOI":"10.1177\/11795735211036576","article-title":"Early Identification, Intervention and Management of Post-Stroke Spasticity: Expert Consensus Recommendations","volume":"13","author":"Bavikatte","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/10749357.2020.1843845","article-title":"Early Clinical Predictors of Post Stroke Spasticity","volume":"28","author":"Ri","year":"2021","journal-title":"Top. Stroke Rehabil."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0269215520963855","article-title":"Can the Early Use of Botulinum Toxin in Post Stroke Spasticity Reduce Contracture Development? A Randomised Controlled Trial","volume":"35","author":"Lindsay","year":"2020","journal-title":"Clin. Rehabil."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Picelli, A., Santamato, A., Cosma, M., Baricich, A., Chisari, C., Millevolte, M., Prete, C.D., Mazz\u00f9, I., Girardi, P., and Smania, N. (2021). Early Botulinum Toxin Type A Injection for Post-Stroke Spasticity: A Longitudinal Cohort Study. Toxins, 13.","DOI":"10.3390\/toxins13060374"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ijge.2018.05.005","article-title":"Post-Stroke Spasticity: A Review of Epidemiology, Pathophysiology, and Treatments","volume":"12","author":"Kuo","year":"2018","journal-title":"Int. J. Gerontol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"ref_48","unstructured":"R Core Team (2024, September 02). R: A Language and Environment for Statistical Computing. Available online: https:\/\/www.R-project.org."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/9\/383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:45Z","timestamp":1760111265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/9\/383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["toxins16090383"],"URL":"https:\/\/doi.org\/10.3390\/toxins16090383","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}